GeneThera Performance
| GTHRDelisted Stock | USD 0.0001 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and GeneThera are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days GeneThera has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable technical indicators, GeneThera is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
GeneThera |
GeneThera Relative Risk vs. Return Landscape
If you would invest 0.01 in GeneThera on November 12, 2025 and sell it today you would earn a total of 0.00 from holding GeneThera or generate 0.0% return on investment over 90 days. GeneThera is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than GeneThera, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
GeneThera Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GeneThera for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GeneThera can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GeneThera is not yet fully synchronised with the market data | |
| GeneThera has some characteristics of a very speculative penny stock | |
| GeneThera has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company shares are held by company insiders |
GeneThera Fundamentals Growth
GeneThera Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of GeneThera, and GeneThera fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GeneThera Pink Sheet performance.
| Return On Asset | -95.38 | |||
| Current Valuation | 1.44 M | |||
| Shares Outstanding | 35.33 M | |||
| Price To Earning | (0.17) X | |||
| EBITDA | (1 M) | |||
| Cash And Equivalents | 140.1 K | |||
| Total Debt | 806.87 K | |||
| Book Value Per Share | (0.24) X | |||
| Cash Flow From Operations | (8.57 K) | |||
| Earnings Per Share | (0.03) X | |||
| Total Asset | 6.3 K | |||
| Retained Earnings | (25.59 M) | |||
| Current Asset | 55 K | |||
| Current Liabilities | 7.08 M | |||
About GeneThera Performance
Assessing GeneThera's fundamental ratios provides investors with valuable insights into GeneThera's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the GeneThera is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
GeneThera, Inc., a biotechnology company, develops molecular assays and therapeutics for the detection and treatment of zoonotic diseases. The companys Molecular RoboticAI Platform and Therapeutic strategy is designed to prevent the spread of disease from animals and allow to better control of zoonotic infectious agents. Genethera operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.Things to note about GeneThera performance evaluation
Checking the ongoing alerts about GeneThera for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for GeneThera help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GeneThera is not yet fully synchronised with the market data | |
| GeneThera has some characteristics of a very speculative penny stock | |
| GeneThera has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (1.01 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GeneThera currently holds about 140.1 K in cash with (8.57 K) of positive cash flow from operations. | |
| Roughly 18.0% of the company shares are held by company insiders |
- Analyzing GeneThera's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GeneThera's stock is overvalued or undervalued compared to its peers.
- Examining GeneThera's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GeneThera's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GeneThera's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GeneThera's pink sheet. These opinions can provide insight into GeneThera's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in GeneThera Pink Sheet
If you are still planning to invest in GeneThera check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the GeneThera's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |